ERBB2 and carcinoma of esophagus: In agreement with the benefit of targeting NRF2 to eliminate the oesophageal cancer cell population that persists after anti-HER2 therapies, we demonstrated that administration of brusatol blocked the growth of lapatinib resistant oesophageal tumour grafts (Fig. 7).